ArticleFrontiers in pharmacology2020
Open Innovation in Medical and Pharmaceutical Research: A Literature Landscape Analysis.
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immunotherapy for ocular melanoma: a bibliometric and visualization analysis from 1991 to 2022.Frontiers in oncology · 2023Pooled it
- Article
- Pharmacology through the lens of bibliometrics: global trends, research hotspots, and collaborations (2015-2026).Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Proceedings from the First Onco Summit: LATAM Chapter, 19-20 May 2023, Rio de Janeiro, Brazil.Cancers · 2024Article
- A data-driven machine learning approach for discovering potent LasR inhibitors.Bioengineered · 2023Article
- Target 2035 - an update on private sector contributions.RSC medicinal chemistry · 2023Article
- Bibliometric analysis of global research trends between gut microbiota and pancreatic cancer: from 2004 to 2023.Frontiers in microbiology · 2023Review
- Knowledge structure and hotspots research of glioma immunotherapy: a bibliometric analysis.Frontiers in oncology · 2023Article
- Bibliometric analysis of electroencephalogram research in mild cognitive impairment from 2005 to 2022.Frontiers in neuroscience · 2023Review
- Developing a national pharmaceutical research strategy in Lebanon: opportunities to bridge the gaps and reach the goals.Journal of pharmaceutical policy and practice · 2022Article
- Tell Us! A survey of public opinion on how to deal with COVID-19 risks and subsequent harm.Public health action · 2022Article
- Digital Teaching in Medical Education: Scientific Literature Landscape Review.JMIR medical education · 2022Article
- Mapping knowledge landscapes and emerging trends of sonodynamic therapy: A bibliometric and visualized study.Frontiers in pharmacology · 2022Article
- Mapping Knowledge Landscapes and Emerging Trends of the Links Between Bone Metabolism and Diabetes Mellitus: A Bibliometric Analysis From 2000 to 2021.Frontiers in public health · 2022Review
- Mapping Knowledge Structure and Global Research Trends in Gout: A Bibliometric Analysis From 2001 to 2021.Frontiers in public health · 2022Article
- Research trends of mesenchymal stem cells application in orthopedics: A bibliometric analysis of the past 2 decades.Frontiers in public health · 2022Article
- Knowledge mapping of targeted immunotherapy for myasthenia gravis from 1998 to 2022: A bibliometric analysis.Frontiers in immunology · 2022Article
- Current State and Future Directions of Intranasal Delivery Route for Central Nervous System Disorders: A Scientometric and Visualization Analysis.Frontiers in pharmacology · 2021Article
- Mapping Knowledge Structure and Research Frontiers of Ultrasound-Induced Blood-Brain Barrier Opening: A Scientometric Study.Frontiers in neuroscience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Open innovation in medical and pharmaceutical research has grown steadily over the last decade. However, the performance of the published literature in terms of the scientific impact and gaining social media attention remains largely unexplored. The scientific literature of open innovation was examined by means of bibliometric analyses to identify the most prolific authors, organizations, countries, journals, research areas, and recurring terms. By accessing the Web of Science Core Collection and Altmetric electronic databases, citation-related and Altmetric data were evaluated. Public-private partnerships and a selection of newly introduced potential novel drugs in the analyzed publications were identified. North America and Europe were the major literature contributors. Research outputs were mainly published in journals focused on business and economics, pharmacology and pharmacy, and engineering. Many pharmaceutical and biotechnological companies contributed to the analyzed publications, with higher mean citation counts and social media attention (Altmetric score) than nonindustry articles. Public-private partnerships fostered financial support, sharing of expertise and intellectual property, and research collaborations. In summary, open innovation might serve as a powerful strategy to both benefit the involved industry entities and accelerate the development of solutions and products for the betterment of human health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.